Castle Biosciences, Inc.
NASDAQ:CSTL
30.53 (USD) • At close September 19, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 Q3 | 2023 Q2 | 2023 Q1 | 2022 Q4 | 2022 Q3 | 2022 Q2 | 2022 Q1 | 2021 Q4 | 2021 Q3 | 2021 Q2 | 2021 Q1 | 2020 Q4 | 2020 Q3 | 2020 Q2 | 2020 Q1 | 2019 Q4 | 2019 Q3 | 2019 Q2 | 2019 Q1 | 2018 Q4 | 2018 Q3 | 2018 Q2 | 2018 Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 87.002 | 72.974 | 66.12 | 61.493 | 50.138 | 42.037 | 38.338 | 37.011 | 34.838 | 26.852 | 25.039 | 23.475 | 22.758 | 22.813 | 17.299 | 15.217 | 12.715 | 17.418 | 17.635 | 14.775 | 10.739 | 8.717 | 11.436 | 3.712 | 3.979 | 3.659 |
| Cost of Revenue
| 17.23 | 16.579 | 15.094 | 11.319 | 11.058 | 10.182 | 9.52 | 8.859 | 7.686 | 5.944 | 4.597 | 4.5 | 3.697 | 3.028 | 2.673 | 2.475 | 2.146 | 2.391 | 2.011 | 1.709 | 1.993 | 1.598 | 1.366 | 1.351 | 1.327 | 1.253 |
| Gross Profit
| 69.772 | 56.395 | 51.026 | 50.174 | 39.08 | 31.855 | 28.818 | 28.152 | 27.152 | 20.908 | 20.442 | 18.975 | 19.061 | 19.785 | 14.626 | 12.742 | 10.569 | 15.027 | 15.624 | 13.066 | 8.746 | 7.119 | 10.07 | 2.361 | 2.653 | 2.406 |
| Gross Profit Ratio
| 0.802 | 0.773 | 0.772 | 0.816 | 0.779 | 0.758 | 0.752 | 0.761 | 0.779 | 0.779 | 0.816 | 0.808 | 0.838 | 0.867 | 0.845 | 0.837 | 0.831 | 0.863 | 0.886 | 0.884 | 0.814 | 0.817 | 0.881 | 0.636 | 0.667 | 0.658 |
| Reseach & Development Expenses
| 14.051 | 13.455 | 12.91 | 12.923 | 13.308 | 14.393 | 11.309 | 10.907 | 11.926 | 10.761 | 9.445 | 7.5 | 6.793 | 5.908 | 4.581 | 3.058 | 2.704 | 2.913 | 3.159 | 1.515 | 1.317 | 1.394 | 1.138 | 1.294 | 1.159 | 1.263 |
| General & Administrative Expenses
| 18.413 | 17.951 | 17.126 | 16.123 | 16.429 | 16.817 | 30.155 | 14.238 | 15.917 | 0 | 0 | 0 | 0 | 0 | 14.959 | 11.703 | 10.392 | 11.078 | 9.852 | 7.122 | 6.821 | 6.047 | 0 | 3.918 | 4.16 | 4.228 |
| Selling & Marketing Expenses
| 32.675 | 30.544 | 26.964 | 28.496 | 28.252 | 29.945 | -43.969 | 22.388 | 21.581 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| SG&A
| 50.709 | 48.411 | 43.774 | 44.619 | 44.681 | 46.762 | 38.426 | 36.626 | 37.498 | 30.453 | 25.16 | 22.595 | 20.822 | 18.161 | 14.959 | 11.703 | 10.392 | 11.078 | 9.852 | 7.122 | 6.821 | 6.047 | 4.164 | 3.918 | 4.16 | 4.228 |
| Other Expenses
| 2.247 | 2.247 | 2.271 | 2.272 | 2.248 | 2.222 | 2.215 | 2.306 | 2.097 | 4.21 | 5.605 | 0.694 | 0.256 | 0 | 0 | 0 | 0 | 0 | -0 | -2.71 | -0.19 | -0.033 | -0.243 | -0.043 | 0.034 | -0.021 |
| Operating Expenses
| 64.76 | 61.866 | 56.684 | 59.814 | 60.237 | 63.377 | 51.95 | 49.839 | 51.521 | 45.424 | 35.613 | 30.789 | 27.871 | 24.069 | 17.658 | 16.643 | 11.214 | 13.991 | 13.011 | 8.637 | 8.138 | 7.44 | 5.302 | 5.213 | 5.319 | 5.49 |
| Operating Income
| 5.012 | -5.471 | -5.658 | -9.64 | -21.157 | -31.522 | -23.132 | -21.687 | -24.369 | -24.516 | -15.171 | -11.814 | -8.81 | -4.284 | -3.032 | -3.901 | -0.645 | 1.036 | 2.613 | 4.429 | 0.608 | -0.321 | 4.767 | -2.852 | -2.666 | -3.085 |
| Operating Income Ratio
| 0.058 | -0.075 | -0.086 | -0.157 | -0.422 | -0.75 | -0.603 | -0.586 | -0.699 | -0.913 | -0.606 | -0.503 | -0.387 | -0.188 | -0.175 | -0.256 | -0.051 | 0.059 | 0.148 | 0.3 | 0.057 | -0.037 | 0.417 | -0.768 | -0.67 | -0.843 |
| Total Other Income Expenses Net
| 2.874 | 2.982 | 3.117 | 2.767 | 2.396 | 2.332 | 2.571 | 1.438 | 20.764 | 0.027 | 0.001 | 0.023 | 0.024 | 0.004 | -1.397 | -0.688 | -0.731 | -0.466 | -0 | 2.503 | -0.19 | -0.033 | -0.243 | -0.043 | 0.034 | -0.021 |
| Income Before Tax
| 7.886 | -2.489 | -2.541 | -6.873 | -18.761 | -29.19 | -20.561 | -20.249 | -3.605 | -24.489 | -15.155 | -11.791 | -8.786 | -4.28 | -4.805 | -4.589 | -1.376 | 0.57 | 2.127 | 5.849 | -1.269 | -1.358 | 3.877 | -3.45 | -3.155 | -3.63 |
| Income Before Tax Ratio
| 0.091 | -0.034 | -0.038 | -0.112 | -0.374 | -0.694 | -0.536 | -0.547 | -0.103 | -0.912 | -0.605 | -0.502 | -0.386 | -0.188 | -0.278 | -0.302 | -0.108 | 0.033 | 0.121 | 0.396 | -0.118 | -0.156 | 0.339 | -0.929 | -0.793 | -0.992 |
| Income Tax Expense
| -1.034 | 0.045 | 0.039 | 0.032 | 0.016 | 0.014 | 0.057 | -1.438 | -1.957 | 0.134 | -8.725 | 0.023 | 0.005 | 0.004 | 0.084 | 0.018 | 0.038 | 0.298 | 0.072 | 306.469 | 995.667 | 0.991 | 0.009 | 0.526 | 0.559 | 0.51 |
| Net Income
| 8.92 | -2.534 | -2.58 | -6.905 | -18.777 | -29.204 | -20.618 | -18.811 | -1.648 | -24.623 | -6.43 | -11.791 | -8.791 | -4.28 | -4.889 | -4.589 | -1.376 | 0.57 | 2.055 | 5.849 | -1.269 | -1.358 | 3.868 | -3.45 | -3.155 | -3.63 |
| Net Income Ratio
| 0.103 | -0.035 | -0.039 | -0.112 | -0.375 | -0.695 | -0.538 | -0.508 | -0.047 | -0.917 | -0.257 | -0.502 | -0.386 | -0.188 | -0.283 | -0.302 | -0.108 | 0.033 | 0.117 | 0.396 | -0.118 | -0.156 | 0.338 | -0.929 | -0.793 | -0.992 |
| EPS
| 0.32 | -0.092 | -0.095 | -0.26 | -0.7 | -1.1 | -0.78 | -0.72 | -0.063 | -0.97 | -0.25 | -0.47 | -0.35 | -0.17 | -0.24 | -0.23 | -0.08 | 0.03 | 0.12 | 0.43 | -0.082 | -0.13 | 0.36 | -0.32 | -0.3 | -0.34 |
| EPS Diluted
| 0.31 | -0.092 | -0.095 | -0.26 | -0.7 | -1.1 | -0.78 | -0.71 | -0.063 | -0.97 | -0.25 | -0.47 | -0.35 | -0.17 | -0.23 | -0.23 | -0.078 | 0.03 | 0.11 | 0.05 | -0.082 | -0.13 | 0.36 | -0.32 | -0.3 | -0.34 |
| EBITDA
| 8.36 | -2.131 | -2.434 | -3.697 | -15.718 | -26.294 | -18.642 | -17.471 | -21.371 | -22.335 | -14.146 | -10.702 | -8.152 | -4.047 | -3.013 | -3.764 | -0.505 | 1.425 | 2.893 | 1.815 | 0.424 | -0.254 | 4.607 | -2.798 | -2.55 | -3.02 |
| EBITDA Ratio
| 0.096 | -0.029 | -0.037 | -0.06 | -0.313 | -0.625 | -0.486 | -0.472 | -0.613 | -0.832 | -0.565 | -0.456 | -0.358 | -0.177 | -0.174 | -0.247 | -0.04 | 0.082 | 0.164 | 0.123 | 0.039 | -0.029 | 0.403 | -0.754 | -0.641 | -0.826 |